Search Results
Found 1 results
510(k) Data Aggregation
(133 days)
The SUPRA SCAN™ Delivery System when connected to a compatible laser system is indicated for use in the treatment of ocular pathology of anterior segments including, retinal photocoagulation, pan retinal photocoagulation for vascular and structural abnormalities of the retina and choroids including:
- · Proliferative and nonproliferative diabetic retinopathy;
- · Choroidal neovascularization;
- · Branch retinal vein occlusion;
- · Age-related macular degeneration;
- · Retinal tears and detachments
- · Macular edema
- · Iridotomy, iridectomy and trabeculoplasty in angle closure glaucoma and open angle glaucoma.
SUPRA SCAN™ Delivery System is a scanning laser delivery system that enables the use of proprietary pattern scanning technology when coupling with laser platforms. This offers existing commercially available laser platform the ability to deliver a full spectrum of pattern scanning options.
The Quantel Medical SUPRA SCAN™ Delivery System consists of the following system components:
-
- Scanning Laser Delivery System adapter with scanner controls that may be coupled to a slit lamp type Haag Streit or similar models, and connected to a currently cleared Quantel Medical 532nm retinal photocoagulator (SUPRA 532).
-
- Scanner control module with LCD/Touch screen, power supply, electronics and electrical connections.
Here's an analysis of the provided text regarding the acceptance criteria and study for the SUPRA SCAN™ Delivery System:
1. Table of Acceptance Criteria and Reported Device Performance
The provided document describes the SUPRA SCAN™ Delivery System's equivalence to a predicate device rather than setting specific numerical acceptance criteria for performance in a clinical study. The "acceptance criteria" here are implicitly whether the device meets the specifications and safety standards of the predicate device, or relevant international and US standards. The "reported device performance" is essentially a comparison of its technical specifications to those of the predicate.
Given the nature of the submission (510(k) for substantial equivalence), the acceptance criteria are primarily that the device's technical characteristics, safety profile, and intended use are sufficiently similar to the predicate device.
| Characteristic / Acceptance Criteria (Implicit) | SUPRA SCAN™ Delivery System Performance | Predicate Device (PASCAL Synthesis™) Performance | Comparison / Outcome |
|---|---|---|---|
| Intended Use | Photocoagulation of anterior and posterior segments of the eye for various ocular pathologies. | Photocoagulation of anterior and posterior segments of the eye for various ocular pathologies. | Equivalent |
| Laser Energy Source | Frequency doubled Nd:YAG | Frequency doubled Nd:YAG | Equivalent |
| Laser Energy Delivery | Single spot & Multi spot | Single spot & Multi spot | Equivalent |
| Spot Placement | Centered on Guide Beam | Centered on Guide Beam | Equivalent |
| Laser energy Intensity | Selected by Physician | Selected by Physician | Equivalent |
| Pulsing System | Continuous | Continuous | Equivalent |
| Output Wavelength | 532 nm | 532 nm | Equivalent |
| Average Power (AP) | 2W (with SUPRA Scan) | 2 W | Equivalent |
| Laser Safety Class | 4/IV | 4/IV | Equivalent |
| Exposure Selections (t) | 0.007s to continuous | 0.01s to continuous | Slightly broader range for SUPRA SCAN, but considered equivalent/safe. |
| Cooling Method | Solid State Cooling with thermoelectric (Peltier) heat pump | Air cooled | Different, but considered safe and effective to meet performance. |
| Aiming Beam Type | Red diode | Red diode | Equivalent |
| Aiming Beam Wavelength | 635 nm | 635 nm | Equivalent |
| Aiming laser power | < 1mW | < 1mW | Equivalent |
| Laser Safety Class (Aiming Beam) | 2/II | 2/II | Equivalent |
| Power calibration | YES | YES | Equivalent |
| Mini focal spot size diameter (Multi-Spot) | 100μm | 100μm | Equivalent |
| Exposure Selections (Multi-Spot) | 0.01s to continuous | 0.01s to continuous | Equivalent |
| Mini focal spot size diameter (Multi-Spot) | 500 µm | 400 μm | Different (SUPRA SCAN has larger max). Stated as "not clinically significant" as SUPRA SCAN can treat at 400µm. |
| Mini focal spot size diameter (Single-Spot) | 50μm | 60 μm | Different, but within acceptable range for treatment. |
| Exposure Selections (Single-Spot) | 0.007s to continuous | 0.01s to continuous | Slightly broader range for SUPRA SCAN, but considered equivalent/safe. |
| Repetition rate between two spots | 8ms | 8ms | Equivalent |
| Type of scanning system | Scanners | Scanners | Equivalent |
| Filter protection integrated | YES | YES | Equivalent |
| Compliance to Standards | IEC 60825-1, IEC 60601-2-22, IEC 60601-1, IEC 60601-1-2, IEC 60601-1-4, EU Directive 93/42/EEC, US Federal Performance Standards 21 CFR 1002.10, Part 820, ISO 9001, 13485 | IEC 60601-2-22, IEC 60825-1 | Equivalent safety and performance standards compliance. |
2. Sample Size Used for the Test Set and Data Provenance
The document explicitly states: "Clinical Conclusion: No Clinical information is required." This indicates that no clinical test set (i.e., human patient data) was used for this 510(k) submission. Therefore, there is no sample size for a test set, nor data provenance (country of origin, retrospective/prospective).
The evaluation was based on non-clinical performance data, which involved laboratory testing to validate and verify that the device met all design specifications and was substantially equivalent to the predicate device. The provenance of this non-clinical testing data would be from the manufacturer's (Quantel Medical, France) internal labs.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts
As no clinical data or test set involving human patients was used, no experts were used to establish ground truth for a clinical test set. The evaluation relied on technical specification comparisons and adherence to established engineering and safety standards.
4. Adjudication Method for the Test Set
Since no clinical test set was utilized requiring expert interpretation, no adjudication method was employed.
5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Status and Effect Size
No MRMC comparative effectiveness study was done. The submission solely focuses on demonstrating substantial equivalence to a predicate device through technical and safety performance comparisons, not on evaluating human reader improvement with AI assistance.
6. Standalone (Algorithm Only Without Human-in-the-Loop Performance) Status
This device is a laser delivery system, not an AI algorithm. Therefore, the concept of "standalone (algorithm only)" performance is not applicable in this context. The device is intended for use by a trained ophthalmologist (human-in-the-loop product).
7. Type of Ground Truth Used
For this 510(k) submission, the "ground truth" was established by engineering specifications, international and US safety standards, and the technical characteristics of the predicate device. The primary ground truth was compliance with these established benchmarks rather than clinical outcomes or expert consensus on clinical findings.
8. Sample Size for the Training Set
No training set data is mentioned or relevant, as this is a physical medical device, not an AI/machine learning algorithm that requires training data.
9. How the Ground Truth for the Training Set Was Established
Not applicable, as there is no training set for this type of device.
Ask a specific question about this device
Page 1 of 1